A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001
in participants at risk for or with frontotemporal dementia due to heterozygous mutations in
the progranulin gene.